Sunday, May 5, 2024 5/5/2024

Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates

Award Number: R44HL134429
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

ABSTRACT Funding is requested to support essential steps required to commercialize 3P-001, a medical device that generates medical grade nitric oxide (NO) from air. NO is a pulmonary vasodilator to treat hypoxic respiratory failure (HRF) in neonates (blue babies) and pulmonary hypertension in patients having cardiothoracic surgery (CTS). Third Pole’s value proposition is that availability of a tank-less iridium-electrode NO generator will greatly expand the use of inhaled nitric oxide (iNO) therapy to treat HRF (approved in both the USA and EU) and during CTS (approved in the EU). The goal is to replace use of pressurized tanks of NO in N2 as the source of medical grade NO. The current tank system requires prolonged set-up times and a complicated supply chain. 3P-001 is tank-less, requiring only electricity and air to produce medical grade NO. It can be deployed quickly and easily (plug and play). The aims of this Phase IIB Bridging Award Application are: Aim 1: Validate 3P-001 for use with commonly-used ventilators and other devices. 3P-001 will be tested with an expanding list of pediatric and adult ventilators for regulatory submission. It will also be validated for use with anesthesia machines, artificial manual breathing units, nasal cannulas, masks, through bench testing for safety and effectiveness of NO delivery. Aim 2: Perform a clinical study in HRF to evaluate safety and effectiveness. It is anticipated that the EU authorities will require a study evaluating safety and effectiveness in patients with HRF, while FDA does not currently require a clinical study in HRF for market authorization. The study will also promote market adoption. This study will be planned and implemented with the help of InClin, a contract research organization (CRO). Aim 3: Perform a clinical study in adult cardiothoracic surgery to evaluate safety and effectiveness. iNO is frequently used during heart/lung transplantation, valve surgery and left ventricular assist device implantation. It is anticipated that the EU authorities will require a cardiac surgery study. This will also address potential FDA concern about safety of 3P-001 use in cardiac surgery, the most common clinical use worldwide, and also promote market adoption in the EU. This study will be planned and implemented with the help of InClin. Aim 4: Validate the 3P-001 ambulatory device for transportation. This is vital to exploit the advantages of 3P-001 for patient transport by land and/or air. Studies will include subjecting 3P-001 to environmental challenges such as acceleration, vibration, altitude, temperature and impact to confirm that the device remains safe and functions as intended using parameters defined by a variety of validating agencies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	THIRD POLE, INC.	309 WAVERLEY OAKS RD	WALTHAM	MA	02452	MIDDLESEX	USA	Lung Diseases Research	001	5	4/8/2024	NON-COMPETING CONTINUATION	$0
2024	2021	THIRD POLE, INC.	309 WAVERLEY OAKS RD STE 404	WALTHAM	MA	02452	MIDDLESEX	USA	Lung Diseases Research	000	5	2/1/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	THIRD POLE, INC.	309 WAVERLY OAKS RD STE 404	WALTHAM	MA	02452	MIDDLESEX	USA	Lung Diseases Research	000	5	9/1/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $979,641 )
2021	2021	THIRD POLE, INC.	309 WAVERLY OAKS RD STE 404	WALTHAM	MA	02452	MIDDLESEX	USA	Lung Diseases Research	001	5	8/19/2021	NON-COMPETING CONTINUATION	$979,641
2021	2017	THIRD POLE, INC.	309 WAVERLY OAKS RD STE 404	WALTHAM	MA	02452	MIDDLESEX	USA	Lung Diseases Research	000	2	7/1/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $979,641

Issue Date FY: 2020 ( Subtotal = $988,472 )
2020	2020	THIRD POLE, INC.	5 WATER ST # 3	ARLINGTON	MA	02476	MIDDLESEX	USA	Lung Diseases Research	001	4	8/26/2020	NON-COMPETING CONTINUATION	$988,472
2020	2019	THIRD POLE, INC.	5 WATER ST # 3	ARLINGTON	MA	02476	MIDDLESEX	USA	Lung Diseases Research	000	3	8/26/2020	COMPETING CONTINUATION	$0
														Subtotal = $988,472

Issue Date FY: 2019 ( Subtotal = $999,466 )
2019	2019	THIRD POLE, INC.	5 WATER ST # 3	ARLINGTON	MA	02476	MIDDLESEX	USA	Lung Diseases Research	000	3	8/19/2019	COMPETING CONTINUATION	$999,466
														Subtotal = $999,466

Issue Date FY: 2017 ( Subtotal = $744,522 )
2017	2017	THIRD POLE, INC.	350 PARNASSUS AVE STE 900	SAN FRANCISCO	CA	94117	SAN FRANCISCO	USA	Lung Diseases Research	000	2	7/24/2017	NON-COMPETING CONTINUATION	$744,522
														Subtotal = $744,522

Issue Date FY: 2016 ( Subtotal = $754,483 )
2016	2016	THIRD POLE, INC	1256 4TH AVE	SAN FRANCISCO	CA	94122	SAN FRANCISCO	USA	Cardiovascular Diseases Research	000	1	8/22/2016	NEW	$754,483
														Subtotal = $754,483

Grand Total All Awards = $4,466,584

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates

Award Number: R44HL134429

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer